September 11, 2025

Treatment of Anal Precancer May Lower Cancer Risk in HIV

Routine screening now includes anoscopy to confirm positive anal Pap or HPV test results.

Conexiant

August 22, 2025

Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation

In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes with alpelisib plus olaparib vs single-agent chemotherapy ...

The ASCO Post

August 22, 2025

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers

In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with ad...

The ASCO Post

June 27, 2025

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

The phase III NRG Oncology GOG-0263 trial—results of which were presented during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer—examined whether...

The ASCO Post

March 29, 2023

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse eve...

The ASCO Post

May 11, 2023

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting

Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.

Dana-Farber

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

Exciting updates from the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer highlight significant improvements in advanced or recurrent endometrial cancer treatment, particularly for patients with specific genetic profiles. Leading expert Dr. Gini F. Fleming shares insights on new approaches and ongoing trials.

The ASCO Post

May 11, 2023

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

A new Wee1 kinase inhibitor, adavosertib, showed promising antitumor activity but also raised safety concerns in patients with recurrent or persistent uterine serous carcinoma. The findings were presented by Joyce F. Liu, MD, MPH at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer.

The ASCO Post